BCIQ Profiles

Company Profile Report
0427 Imab UC
BioCentury & Getty Images

Product Development

I-Mab’s IL-6 inhibitor for ulcerative colitis could differentiate on safety

Apr 28, 2021 | 12:06 AM GMT

By selectively blocking an IL-6/IL-6R complex that arises during chronic inflammation, I-Mab’s olamkicept managed to demonstrate clinical response

Read the full 415 word article

How to gain access

Continue reading with a
two-week free trial.